Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

219
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
219
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

231
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
231
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Relacorilant: First Approval.

Drugs·2026
Same author

Rovadicitinib: First Approval.

Drugs·2026
Same author

Sonrotoclax: First Approval.

Drugs·2026
Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026
Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026
Same author

Lerodalcibep: First Approval.

Drugs·2026

相关实验视频

Updated: Jan 6, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

弗雷曼祖马布:为儿童首次获得批准

Hannah A Blair1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.

Paediatric drugs
|September 29, 2025
PubMed
概括

针对色素基因相关的单克隆抗体Fremanezumab现在已批准用于预防6至17岁儿童患者的偶发性偏头痛. 这标志着对年轻人偏头痛治疗的重要里程碑.

科学领域:

  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.
  • 免疫学 免疫学 免疫学

背景情况:

  • 偏头痛是一种复杂的神经疾病,影响全球数百万人.
  • 素基因相关 (CGRP) 在偏头痛病理生理学中起着至关重要的作用.
  • 儿童偏头痛的现有治疗方法存在局限性,需要新的治疗选择.

研究的目的:

  • 总结一个针对CGRP的单克隆抗体fremanezumab的发展.
  • 突出了导致弗雷曼祖马布用于偏头痛预防的儿科批准的里程碑.
  • 提供弗雷曼尼祖马布从开发到扩展指示的旅程的概述.

主要方法:

  • 对 fremanezumab 的临床试验数据和监管机构提交的意见的审查.
  • 对针对CGRP的framanezumab的作用机制的分析.
  • 对儿科患者群体的药理动力学和药理动力学概况的检查.

主要成果:

  • 弗雷曼祖马布是一种人性化的单克隆抗体,可以选择性地向CGRP.
  • 该药物于2018年获得美国FDA批准用于成人偏头痛预防.
  • 在2025年8月,弗雷曼祖马布获得批准用于小儿病患者 (6-17岁,≥45公斤) 的偶发性偏头痛预防.

更多相关视频

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.1K
Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

12.5K

相关实验视频

Last Updated: Jan 6, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.1K
Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

12.5K

结论:

  • 弗雷曼祖马布在儿科患者的偏头痛管理方面取得了重大进展.
  • 针对性抑制CGRP提供了一个新的治疗策略,用于偶发性偏头痛.
  • 这项儿科批准扩大了弱势患者群体的治疗选择.